Penn Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.5M Sell
286,281
-12,633
-4% -$1.32M 1.78% 5
2026
Q2
$35.1M Buy
298,914
+42,147
+16% +$4.23M 2.22% 3
2026
Q1
$23.8M Sell
256,767
-25,151
-9% -$2.37M 1.84% 1
2025
Q4
$22.3M Sell
281,918
-26,073
-8% -$1.87M 1.78% 3
2025
Q3
$22.6M Sell
307,991
-34,265
-10% -$2.18M 1.74% 4
2025
Q2
$17.5M Sell
342,256
-31,263
-8% -$1.39M 1.51% 17
2025
Q1
$16.9M Buy
373,519
+95,092
+34% +$4.48M 1.64% 12
2024
Q4
$11.5M Sell
278,427
-30,817
-10% -$1.28M 1.13% 42
2024
Q3
$12.1M Buy
309,244
+68,093
+28% +$2.72M 1.11% 42
2024
Q2
$8.26M Sell
241,151
-4,545
-2% -$119K 0.78% 62
2024
Q1
$6.18M Sell
245,696
-32
-0% -$880 0.55% 71
2023
Q4
$7.26M Sell
245,728
-242
-0.1% -$7.32K 0.67% 68
2023
Q3
$7.78M Buy
245,970
+6,696
+3% +$183K 0.8% 62
2023
Q2
$6.19M Buy
+239,274
New +$6.36M 0.6% 68

Other funds holding MIRM

Penn Capital Management's MIRM Position: Q3 2026 in Review

Penn Capital Management reduced its Mirum Pharmaceuticals (MIRM) stake by 4.2% in Q3 2026, selling an estimated $1.32M and leaving 286,281 shares worth $24.5M. The position accounts for 1.78% of the portfolio, ranked #5.

Penn Capital Management first reported a position in MIRM in Q2 2023 and has held it in 14 quarters since. The position peaked at $35.1M in Q2 2026. 314 funds tracked by Wall St. Rank hold MIRM as of Q3 2026.

  • Penn Capital Management held 286,281 shares of Mirum Pharmaceuticals worth $24.5M as of Q3 2026.
  • Penn Capital Management sold 12,633 Mirum Pharmaceuticals shares in Q3 2026, an estimated $1.32M.
  • Mirum Pharmaceuticals made up 1.78% of Penn Capital Management's portfolio in Q3 2026, its #5 holding.
  • Penn Capital Management first reported a position in Mirum Pharmaceuticals in Q2 2023 and has held it in 14 quarters since.
  • Penn Capital Management's Mirum Pharmaceuticals position peaked at $35.1M in Q2 2026.
  • 314 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2026.

Based on Penn Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.